Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 15580219.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Thirteen children with difficult systemic onset juvenile rheumatoid arthritis were treated with thalidomide. At 6 months, 11 of the 13 were able to reduce their use of prednisone ( P < .002), with a concurrent improvement in erythrocyte sedimentation rate ( P < .0001) and an increase in hemoglobin level ( P < 0.005). Juvenile rheumatoid arthritis improvement scores >/=50% were obtained by 10 of the 13 children.
Medical subject headings
- Arthritis, Juvenile
- Immunosuppressive Agents
- Thalidomide